�Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral delivery systems, announced successful results from the clinical visitation of its oral insulin capsule, ORMD 0801. The trial demonstrated that the product had a beneficial safety profile and well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes.
The study was conducted at Hadassah University Medical Center in Jerusalem and was a continuation of the successful Phase 1B trials that Oramed completed earlier this year.
This trial was the first to expose patients with type 2 diabetes to ORMD 0801 and its primary goals were to assess the safety, tolerability and pharmcodynamic effects in these patients.
ORMD 0801 was well tolerated by all patients and had a good safety profile; no good adverse events were encountered throughout the study. In 6 of the 9 subjects analyzed, statistically significant reductions in glucose as well as C-peptide were observed.
"We are pleased with the results from the Phase 2A test as they show that ORMD 0801 was effective and there were no safety issues," said Oramed's Chief Scientist, Dr. Miriam Kidron. "We look forrad to our next stage of examination and taking the succeeding steps towards making an oral insulin capsule a reality for millions of diabetics close to the worldly concern."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines soon delivered via injection. Oramed is seeking to revolutionize the handling of diabetes through its patented flagship product, an orally ingestible insulin ejector seat currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit hTTP://www.oramed.com
Forward-looking statements
Some of the statements contained in this press out release ar forward-looking statements which involve known and unknown risks, uncertainties and other factors which crataegus oxycantha cause the actual results, performance or achievements of the company, or industriousness results, to be materially different from any next results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to to the progress, timing, cost, and results of clinical trials and ware development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from early pharmaceutical or biotechnology companies; and the company's ability to incur additional financial support required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause literal results, carrying out or achievements of the company to differ materially from those expressed or implied in such forth looking statements. The company undertakes no obligation to update or revise whatever forward-looking statements.
Oramed Pharmaceuticals
More information
